At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial
| Autor: | Martin S. Tallman, Susan M. Richards, Xin V. Wang, David I. Marks, Anthony H. Goldstone, Charles G. Mullighan, Jacob M. Rowe, Mark R. Litzow, Georgina Buck, Peter H. Wiernik, Kathryn G. Roberts, Letizia Foroni, Cheryl L. Willman, Dan Douer, Chezi Ganzel, Hillard M. Lazarus, Elisabeth Paietta, Selina M. Luger |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Early Relapse acute lymphoblastic leukemia Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Recurrence Risk Factors Internal medicine Overall survival medicine Humans Autografts Adult all business.industry Incidence (epidemiology) Hematopoietic Stem Cell Transplantation Complete remission Hematology Precursor Cell Lymphoblastic Leukemia-Lymphoma Allografts Haematological Malignancy – Clinical Survival Rate Cumulative risk late relapse 030220 oncology & carcinogenesis Lymphoblastic leukaemia Female Late Relapse business Follow-Up Studies Research Paper 030215 immunology |
| Zdroj: | British Journal of Haematology |
| ISSN: | 1365-2141 0007-1048 |
| Popis: | Summary Late relapse [>3 years from complete remission (CR)] in acute lymphoblastic leukaemia (ALL), is unusual. Data from the MRC UKALLXII/ECOG E2993 trial are presented to evaluate the incidence and characteristics of late relapse in adult ALL. Of 1,909 patients, 1,752 (92%) achieved CR and among these 757 (43·2%) relapsed; 691 (91·3%) within three years and 66 (8·7%) beyond. Among these 66 patients, median time to relapse was 47 (37–144) months. Relapse beyond three years occurred in 3·8% of all who achieved CR. The cumulative risk of relapse was 40%, 43% and 45% at three, five and ten years respectively. Out of the 1 752 patients who achieved CR, 11·7% underwent autologous and 40·6% allogeneic transplant, while in CR1. Of the autologous patients, 43·2% relapsed early and 3·4% relapsed late. However, among the allogeneic patients, 13·2% relapsed early and only 1·3% late. The five‐year overall survival from relapse was 5·8% and 20% in the early and late relapse patients respectively. In conclusion, late relapse in adults with ALL is not uncommon, and is associated with better outcome after relapse compared to early relapse. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text